| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/23/2003 | US20030017965 Methods for treating certain diseases using naaladase inhibitors |
| 01/23/2003 | US20030017617 Mammalian receptor proteins; related reagents and methods |
| 01/23/2003 | US20030017612 Methods and reagents to acquire MRI signals and images |
| 01/23/2003 | US20030017586 Nucleotide sequences coding polypeptide for use in the treatment of viral diseases |
| 01/23/2003 | US20030017218 Soft tissue anticancer agents |
| 01/23/2003 | US20030017215 Soft tissue anticancer agents |
| 01/23/2003 | US20030017214 Solid microbiocides of zinc chloride and cefuroxime axetil |
| 01/23/2003 | US20030017211 Method for drug delivery to the pulmonary system |
| 01/23/2003 | US20030017210 Controlled-release for oral administration of cisplatin |
| 01/23/2003 | US20030017209 Breath protection microcapsules |
| 01/23/2003 | US20030017207 Compositions and methods for treating vulvovaginitis and vaginosis |
| 01/23/2003 | US20030017205 Nutritional tablet of caplet with a coating of a film forming polymer and folic acid; rapid release |
| 01/23/2003 | US20030017202 Brittle-coating, soft core dosage form |
| 01/23/2003 | US20030017201 Pharmaceutical composition comprising entracapone, levodopa, and carbidopa |
| 01/23/2003 | US20030017200 Oral administration of terbinafine, a buffering component and a disintegrant; fungicides |
| 01/23/2003 | US20030017197 Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells |
| 01/23/2003 | US20030017196 Oligonucleotide inhibitors of bcl-xL |
| 01/23/2003 | US20030017191 Reducing postprandial glycemic excursion to carbohydrates by feeding supplemental fructose prior to carbohydrate challenge |
| 01/23/2003 | US20030017188 Administered between 15 and 90 minutes prior to exposure of the subject to thrombogenic stimuli |
| 01/23/2003 | US20030017181 Including one or more anesthetic agents and/or one or more anti-inflammatory agents and/or a combination of ammonium, sodium, and potassium salts, preferably of an alpha-hydroxy acid |
| 01/23/2003 | US20030017177 Topical application of compositions containing an alkanolamine such as ethylaminoethanol, methylaminoethanol |
| 01/23/2003 | US20030017175 Sublingual administration of dihydroergotamine for the treatment of migraine |
| 01/23/2003 | US20030017174 Containing herpes simplex virus VP22 polypeptides capable of eliciting a cellular immune response |
| 01/23/2003 | US20030017166 Combination preparation for the therapy of immunological diseases |
| 01/23/2003 | US20030017164 Dye-azide compounds for dual phototherapy |
| 01/23/2003 | US20030017155 Treating a condition characterized by activation of the inflammatory cytokine cascade |
| 01/23/2003 | US20030017153 Determining whether a patient's immune system can be modified through stimulation of thymus function; sex steroids are ablated in the patient, and the resulting production of thymic factors is monitored. |
| 01/23/2003 | US20030017151 Receptor Activator of NF-kappa B antagonists; treatment of medical conditions that require the formation of new bone. |
| 01/23/2003 | US20030017148 Prevention of insulin-dependent diabetes, complications thereof, or allograft rejection by inhibition of cyclooxygenase-2 activity |
| 01/23/2003 | US20030017145 Treating subjects suffering from herpes virus infections, acquired immunodeficiency syndrome, and hepatitis C infections by administering a compound effective to inhibit the production or release of the ROMs. |
| 01/23/2003 | US20030017136 Pharmaceutical compositions comprising vitamin B12 and interferon-beta for treating multiple sclerosis |
| 01/23/2003 | US20030017135 Pharmaceutical compositions comprising vitamin B12 and interferon for treating multiple sclerosis |
| 01/23/2003 | US20030017131 Preferably a polyethylene glycol-polylactone or -polyhydroxyalkanoate block polymer reacted with a linker and the target drug, especially an anticancer drug |
| 01/23/2003 | US20030017130 A hydroxycarboxylic acid is present in the form of a free acid, lactone, or salt and a retinoid in stereoisomeric or non-isomeric form |
| 01/23/2003 | US20030017120 Delivery of erectile dysfunction drugs through an inhalation route |
| 01/23/2003 | US20030017119 Aerosol comprises particles comprising at least 10 percent by weight of an opioid, and wherein the opioid is not heroin; opiods include morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, etc. |
| 01/23/2003 | US20030017118 An aerosol for inhalation therapy, wherein the aerosol comprises particles comprising at least 10 percent by weight of an antipsychotic such as olanzapine, trifluoperazine, haloperidol, loxapine, clozapine, quetiapine, promazine, etc. |
| 01/23/2003 | US20030017117 Delivery of analgesics through an inhalation route |
| 01/23/2003 | US20030017116 Delivery of sedative-hypnotics through an inhalation route |
| 01/23/2003 | US20030017115 Aerosol comprises particles comprising at least 10 percent by weight of a drug ester. |
| 01/23/2003 | US20030017114 Aerosol comprises particles of chlordiazepoxide, betahistine, clonidine, testosterone, conjugated estrogens, estrogen esters, estradiol, estradiol esters, ethinyl estradiol, ethinyl estradiol esters, or hyoscyamine. |
| 01/23/2003 | US20030016620 Slider for an optical head with a terminal groove having an inclined bottom surface |
| 01/23/2003 | US20030015197 Method of forming an aerosol for inhalation delivery |
| 01/23/2003 | US20030015196 Aerosol forming device for use in inhalation therapy |
| 01/23/2003 | US20030015190 Delivery of compounds for the treatment of migraine through an inhalation route |
| 01/23/2003 | US20030015189 Delivery of antihistamines through an inhalation route |
| 01/23/2003 | CA2821544A1 Use of follistatin for the treatment of pulmonary fibrosis and fibrosis associated with inflammatory bowel disease |
| 01/23/2003 | CA2777199A1 Methods and materials for the treatment of testosterone deficiency in men |
| 01/23/2003 | CA2752782A1 Electroencephalography based systems and methods for selecting therapies and predicting outcomes |
| 01/23/2003 | CA2454135A1 Gpcs as modifiers of the irrtk and p21 pathways and methods of use |
| 01/23/2003 | CA2454106A1 Mixed complexes for masking the taste of bitter active substances |
| 01/23/2003 | CA2453784A1 A core formulation |
| 01/23/2003 | CA2453782A1 Core formulation comprising troglitazone and a biguanide |
| 01/23/2003 | CA2453775A1 Core formulation comprising pioglitazone hydrochloride and a biguanide |
| 01/23/2003 | CA2453554A1 Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands |
| 01/23/2003 | CA2453531A1 Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells |
| 01/23/2003 | CA2453503A1 N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds |
| 01/23/2003 | CA2453470A1 Use of follistatin for the treatment of hepatic fibrogenesis |
| 01/23/2003 | CA2453467A1 Method for isolating terpene trilactones (ginkgolides, bilobalide) from leaves and pharmaceutical powders of ginkgo biloba |
| 01/23/2003 | CA2453451A1 Aminediols for the treatment of alzheimer's disease |
| 01/23/2003 | CA2453447A1 Alpha-hydroxyamide statine derivatives for the treatment of alzheimer's disease |
| 01/23/2003 | CA2453444A1 Diaminediols for the treatment of alzheimer's disease |
| 01/23/2003 | CA2453435A1 Human mini-antibody cytotoxic for tumor cells which express the erbb2 receptor |
| 01/23/2003 | CA2453403A1 Methods of inhibiting amyloid toxicity |
| 01/23/2003 | CA2453399A1 Combinations for the treatment of inflammatory disorders |
| 01/23/2003 | CA2453389A1 Aerosol formulations of .delta.8 tetrahydrocannabinol |
| 01/23/2003 | CA2453362A1 Oligonucleotide-containing pharmacological compositions and their use |
| 01/23/2003 | CA2453357A1 Anti-neoplastic viral agents |
| 01/23/2003 | CA2453346A1 A hydroxamic acid thrombospondin peptide analog that inhibits aggrecanase activity |
| 01/23/2003 | CA2453340A1 .beta.-adrenergic blockade reversal of catabolism after severe burn |
| 01/23/2003 | CA2453308A1 Pharmaceutical compositions for oral use, containing, in combination, metformin and glicazide |
| 01/23/2003 | CA2453183A1 In vivo production of small interfering rnas that mediate gene silencing |
| 01/23/2003 | CA2453182A1 Crystalline thiazine oxazolidinones |
| 01/23/2003 | CA2453175A1 Interaction inhibitors of tcf-4 with beta-catenin |
| 01/23/2003 | CA2453159A1 A composition and uses therefor for combating hangover |
| 01/23/2003 | CA2453153A1 A method of treatment and/or prophylaxis of ulcers |
| 01/23/2003 | CA2453147A1 Methods of treating cytokine mediated diseases |
| 01/23/2003 | CA2453111A1 Pharmaceutical formulation for the intramuscular administration of fulvestrant |
| 01/23/2003 | CA2453090A1 A composition for use in prophylaxis and/or treatment |
| 01/23/2003 | CA2453083A1 A method for treatment and/or prophylaxis |
| 01/23/2003 | CA2452612A1 Novel anticonvulsant derivative salts |
| 01/23/2003 | CA2452610A1 Hexahydroazepino (4, 5-g) indoles and indolines as 5-ht receptor ligands |
| 01/23/2003 | CA2452544A1 Method for treating secondary tissue degeneration associated with central nervous system injury |
| 01/23/2003 | CA2452513A1 Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound |
| 01/23/2003 | CA2452491A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 01/23/2003 | CA2451776A1 Enhancement of the stability of oligonucleotides comprising phosphorothioate linkages by addition of water-soluble antioxidants |
| 01/23/2003 | CA2451670A1 Enteral formulations |
| 01/23/2003 | CA2451569A1 Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
| 01/23/2003 | CA2451566A1 Use of nk-1 receptor antagonists for the treatment of brain, spinal or nerve injury |
| 01/23/2003 | CA2451469A1 Use of antimicrobial peptides as preservatives in ophthalmic preparations including solutions emulsions and suspensions |
| 01/23/2003 | CA2450898A1 Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus |
| 01/23/2003 | CA2449504A1 Bridged bicyclic serine protease inhibitors |
| 01/23/2003 | CA2448558A1 Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery |
| 01/23/2003 | CA2448553A1 A pharmaceutical composition comprising a nicotinic receptor partial antagonist and an antiemetic agent of modulating cholinergic function |
| 01/23/2003 | CA2446726A1 Piperazine oxime derivatives having nk-1 receptor antagonistic activity |
| 01/23/2003 | CA2444089A1 Biocompatible composite |
| 01/23/2003 | CA2418173A1 N-substituted-1-amino-1,1-dialkylcarboxylic acid derivatives |
| 01/23/2003 | CA2417156A1 3,4-dihydroisoquinoline derivative compound and a pharmaceutical agent comprising it as active ingredient |
| 01/22/2003 | EP1277843A2 Novel human genes and gene expression products related to colon cancer |
| 01/22/2003 | EP1277759A1 Cytokine related treatments of disease |